Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) announced its participation in the 44th Annual J.P. Morgan Healthcare Conference, scheduled for Wednesday, 14 January 2026, at the Westin St. Francis in San Francisco, CA, USA. Dr Harald Hasselmann, CEO of Eckert & Ziegler SE, will present the company at 17:15 PST.
The presentation will be available as an audio livestream on the company's website at https://www.ezag.com/investors/presentations/. After the event, the recording will be accessible for approximately 30 days.
This participation underscores Eckert & Ziegler's commitment to engaging with the investment community and showcasing its leadership in isotope-related components for nuclear medicine and radiation therapy. The J.P. Morgan Healthcare Conference is one of the most significant events in the healthcare investment sector, attracting top executives, investors, and analysts from around the world. By presenting at this conference, Eckert & Ziegler gains visibility among key stakeholders, which is crucial for securing investment and partnerships that drive innovation and growth.
Eckert & Ziegler SE, with more than 1,000 employees, is a leading specialist for isotope-related components in nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Its inclusion in the TecDAX index of Deutsche Borse reflects its importance in the technology sector.
The presentation provides an opportunity for investors to gain insights into Eckert & Ziegler's strategic direction, recent achievements, and future plans. Given the growing demand for radiopharmaceuticals in cancer treatment and diagnostic imaging, the company's role in the supply chain is increasingly vital. The conference participation highlights the company's proactive approach to investor relations and its ability to articulate its value proposition to a global audience.
As the healthcare industry continues to evolve, Eckert & Ziegler's presence at such a high-profile conference signals its readiness to capitalize on emerging trends and challenges. The company's focus on saving lives through its contributions to nuclear medicine positions it well for sustained growth. For more information, visit the company's website at https://www.ezag.com.
